Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes

Rationale: Increasing frequency of human exposure to PEG-related products means that healthy people are likely to have pre-existing anti-PEG antibodies (pre-αPEG Ab). However, the influence of pre-αPEG Abs on the pharmacokinetics (PK) and therapeutic efficacy of LipoDox is unknown. Methods: We gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Yuan-Chin, Wang, Hsin-Ell, Lin, Wen-Wei, Roffler, Steve R., Cheng, Ta-Chun, Su, Yu-Cheng, Li, Jia-Je, Chen, Chao-Cheng, Huang, Chun-Han, Chen, Bing-Mae, Wang, Jaw-Yuan, Cheng, Tian-Lu, Chen, Fang-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996368/
https://www.ncbi.nlm.nih.gov/pubmed/29896310
http://dx.doi.org/10.7150/thno.22164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996368/
https://www.ncbi.nlm.nih.gov/pubmed/29896310
http://dx.doi.org/10.7150/thno.22164

Ejemplares similares